Zacks Research Downgrades Siemens Healthineers (OTCMKTS:SMMNY) to Strong Sell

Siemens Healthineers (OTCMKTS:SMMNY) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Other equities analysts have also recently issued reports about the company. Citigroup reiterated a “buy” rating on shares of Siemens Healthineers in a report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Siemens Healthineers in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Siemens Healthineers Price Performance

SMMNY opened at $21.29 on Thursday. Siemens Healthineers has a 52 week low of $19.20 and a 52 week high of $28.92. The business’s fifty day simple moving average is $22.24 and its 200 day simple moving average is $21.06.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a Germany-based medical technology company that develops and supplies products, services and digital solutions for healthcare providers. Its portfolio supports medical imaging, laboratory diagnostics, cancer treatment, minimally invasive procedures and related clinical workflows.

The company’s imaging business offers magnetic resonance imaging, computed tomography, molecular imaging, X-ray and ultrasound systems. Its diagnostics activities include laboratory testing, point-of-care testing and diagnostic IT solutions.